Clinical Trials
78 trialsMOMENTUM-1
RTOG Foundation, Inc.
HU-F-AIM
Novartis
MITHRIDATE
University of Birmingham
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
GIV-IN-PV
Italfarmaco
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
OASIS
Imugene Limited
PROSPERA
Theradex
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
ALLO-BAT
University Health Network, Toronto
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
ISAKIDS
Sanofi
Prospero
Novartis
HUVAMER
Haukeland University Hospital
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
DEPEND
University of Chicago
OPTIMA-II
University of Chicago
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
OPTIMA
University of Chicago
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
University of Chicago
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
SOPRA
Karyopharm Therapeutics Inc
DALIAH
Odense University Hospital
APL16
First Affiliated Hospital Xi'an Jiaotong University
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
UNICANCER
HUTMZ
Amsterdam UMC, location VUmc
PV
Italfarmaco
EPIC
University of Chicago
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Montefiore Medical Center
HU
First Affiliated Hospital of Harbin Medical University
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Heidelberg University
DeCIDE
University of Chicago
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Incyte Corporation
JANORL2
Gustave Roussy, Cancer Campus, Grand Paris
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Children's Hospital of Philadelphia
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
PROUD-PV
AOP Orphan Pharmaceuticals AG
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Alliance for Clinical Trials in Oncology
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
SWOG Cancer Research Network